Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Melanoma.

Trial Profile

Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2012

At a glance

  • Drugs Axitinib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Aug 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 19 Dec 2007 The expected completion date for this trial is now 1 Mar 2008.
    • 01 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top